English
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Basque
Belarusian
Bengali
Bosnian
Bulgarian
Catalan
Cebuano
Chichewa
Chinese (Simplified)
Chinese (Traditional)
Corsican
Croatian
Czech
Danish
Dutch
English
Esperanto
Estonian
Filipino
Finnish
French
Frisian
Galician
Georgian
German
Greek
Gujarati
Haitian Creole
Hausa
Hawaiian
Hebrew
Hindi
Hmong
Hungarian
Icelandic
Igbo
Indonesian
Irish
Italian
Japanese
Javanese
Kannada
Kazakh
Khmer
Korean
Kurdish (Kurmanji)
Kyrgyz
Lao
Latin
Latvian
Lithuanian
Luxembourgish
Macedonian
Malagasy
Malay
Malayalam
Maltese
Maori
Marathi
Mongolian
Myanmar (Burmese)
Nepali
Norwegian
Pashto
Persian
Polish
Portuguese
Punjabi
Romanian
Russian
Samoan
Scottish Gaelic
Serbian
Sesotho
Shona
Sindhi
Sinhala
Slovak
Slovenian
Somali
Spanish
Sudanese
Swahili
Swedish
Tajik
Tamil
Telugu
Thai
Turkish
Ukrainian
Urdu
Uzbek
Vietnamese
Welsh
Xhosa
Yiddish
Yoruba
Zulu
Patent ahụ, nke akpọrọ "Compositions and Methods to Detect GluA1 in Brain and to Identify the Presence of GluA1-Mediated PTSD," ka eduzi na usoro ihe omimi na ụzọ maka ịchọpụta PTSD yana ịgwọ PTSD na-eso ụdị nchoputa ahụ.
"Ngwakọta nke patent a chebere sitere na otu n'ime usoro klaasị nke Neurovation Labs na-etolite iji mee ka nyocha ebumnuche nke PTSD na iji nyochaa usoro ndị na-akpata PTSD na nsogbu ahụike uche ndị ọzọ. Ogige ndị a na ụzọ kwekọrọ ekwekọ nke patent ahụ kpuchiri na-anọchi anya akwụkwọ akụkọ, ụzọ ezubere iche maka ahụike uche na iji anya nke uche na-ahụ maka nsogbu nke ụbụrụ na-akpata, "Dọkịta Jennifer Perusini, Co-Founder & Chief Executive Officer nke ụlọ ọrụ ahụ kwuru.
Ọ bụ naanị Neurovation Labs nwe patent a ma bụrụ nke izizi sitere na Pọtụfoliyo akụrụngwa ọgụgụ isi sara mbara sitere na nyocha na mmepe ụlọ ọrụ.
